0000849146-21-000079.txt : 20210819 0000849146-21-000079.hdr.sgml : 20210819 20210819160731 ACCESSION NUMBER: 0000849146-21-000079 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20210819 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210819 DATE AS OF CHANGE: 20210819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Lifevantage Corp CENTRAL INDEX KEY: 0000849146 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841097796 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35647 FILM NUMBER: 211190175 BUSINESS ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 BUSINESS PHONE: 801-432-9000 MAIL ADDRESS: STREET 1: 3300 TRIUMPH BLVD STREET 2: SUITE 700 CITY: LEHI STATE: UT ZIP: 84043 FORMER COMPANY: FORMER CONFORMED NAME: LIFELINE THERAPEUTICS, INC. DATE OF NAME CHANGE: 20041019 FORMER COMPANY: FORMER CONFORMED NAME: YAAK RIVER RESOURCES INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ANDRAPLEX CORP DATE OF NAME CHANGE: 19920406 8-K 1 lfvn-20210819.htm 8-K lfvn-20210819
0000849146false00008491462020-08-182020-08-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 ______________________________
 FORM 8-K
 ______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 19, 2021
 ______________________________
LIFEVANTAGE CORPORATION
(Exact name of registrant as specified in its charter)
______________________________
Delaware001-3564790-0224471
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)(IRS Employer
Identification No.)
3300 Triumph Blvd, Suite 700
Lehi, Utah 84043
(Address of principal executive offices, including zip code)
(801) 432-9000
(Registrant's telephone number)
_____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Common Stock, par value $0.0001LFVNThe Nasdaq Stock Market LLC
Title of each classTrading Symbol(s)Name of each exchange on which registered
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Item 2.02.    Results of Operations and Financial Condition.
    On August 19, 2021, LifeVantage Corporation (the “Company”) issued a press release announcing its financial results for the fourth quarter and full fiscal year ended June 30, 2021. A copy of the Company’s press release is attached as Exhibit 99.1 to this report and incorporated by reference.
    The information furnished in this Item 2.02 and the exhibit hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d)    Exhibits
Exhibit No.
Description

99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date:
August 19, 2021
LIFEVANTAGE CORPORATION
By:
/s/ Steven R. Fife
Name:
Steven R. Fife
Title:
President, Chief Executive Officer, Chief Financial Officer


EX-99.1 2 lfvnq42021earningsrelease.htm EX-99.1 Document
logoa23a.jpg
LifeVantage Announces Financial Results for the
Fourth Fiscal Quarter and Full Fiscal Year 2021
Revenue of $220 million for Fiscal 2021
Fourth Quarter Adjusted EPS Increased 10.7% Year over Year

Salt Lake City, UT, August 19, 2021, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its fourth quarter and full fiscal year ended June 30, 2021.
Fourth Quarter Fiscal 2021 Summary*:
Revenue of $54.8 million, a decrease of 7.7% from the prior year period and an increase of 6.2% sequentially;
Total active accounts decreased 5.0% compared to the prior period while increasing 1.2% sequentially to 170,000. The year over year decline includes a decline in distributors of 13.7%, partially offset by an increase of 0.9% in customers. Compared to the third quarter of fiscal 2021, the number of distributors was flat and customers grew by 1.9%;
Earnings per diluted share were $0.35, up 34.6% over the prior year period and up 191.7% sequentially;
Adjusted earnings per diluted share were $0.31, up 10.7% compared to $0.28 in the prior year period and up 55.0% sequentially; and
Adjusted EBITDA decreased 19.3% to $6.6 million compared to the prior period and increased 37.9% sequentially.
* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2021 to the fourth quarter of fiscal 2020, unless otherwise noted.
Fiscal Year 2021 Summary**:
Revenue decreased 5.5% to $220.2 million;
Revenue in the Americas decreased 7.0% and revenue in Asia/Pacific & Europe decreased 1.6%;
Earnings per diluted share were $0.90, compared to $0.79 in fiscal 2020;
Adjusted earnings per diluted share were $1.00, compared to $0.86 in fiscal 2020;
Adjusted EBITDA increased 3.7% to $24.8 million;
Repurchased 1.2 million, or $11.9 million, of common shares; and
Strong balance sheet with $23.2 million of cash and no debt.
**All growth rates compare fiscal 2021 to fiscal 2020.
“Fourth quarter revenues results were in line with our expectations and earnings were slightly ahead as we continued to focus on our core strategies for driving long-term growth and operational improvement. Adjusted earnings per share increased 11% despite an 8% decline in net sales,“ said Steve Fife, Chief Executive Officer and Chief Financial Officer of LifeVantage. “The sequential improvement in the number of customers was particularly encouraging and the first positive inflection in the past year. Our initiatives to drive active account growth through distributor enrollment and increased retention continue to gain traction and we expect to show further progress over the next several quarters. Consumers continue prioritizing health and wellness, which we believe creates a compelling long-term growth outlook for LifeVantage based on our proven products, strong balance sheet and deeply committed management team.”


logoa23a.jpg
Fourth Quarter Fiscal 2020 Results
For the fourth fiscal quarter ended June 30, 2021, the Company reported revenue of $54.8 million, a 7.7% decrease over the fourth quarter of fiscal 2020. Revenue in the Americas for the fourth quarter of fiscal 2021 decreased 9.6% compared to the fourth quarter of fiscal 2020 and revenue in the Asia/Pacific & Europe region decreased 3.3% compared to the fourth quarter of fiscal 2020. Revenue for the fourth quarter of fiscal 2021 was positively impacted $0.8 million, or 1.3%, by foreign currency fluctuations associated with revenue generated in international markets when compared to the fourth quarter of fiscal 2020.
Gross profit for the fourth quarter of fiscal 2021 was $45.0 million, or 82.1% of revenue, compared to $49.9 million, or 84.1% of revenue, for the same period in fiscal 2020. The decrease in gross margin as a percentage of revenue is primarily due to increased shipping expenses to customers due to COVID-19, decreased fee revenues as a result of fewer in-person distributor events being held during the current year period due to the COVID-19 pandemic, and shifts in geographic and product sales mix.
Commissions and incentives expense for the fourth quarter of fiscal 2021 was $25.6 million, or 46.7% of revenue, compared to $28.9 million, or 48.7% of revenue, for the same period in fiscal 2020. The decrease in commissions and incentives expense as a percentage of revenue is due mainly to the timing and magnitude of promotional and incentive activities as compared to the prior year quarter.
Selling, general and administrative expense (SG&A) for the fourth quarter of fiscal 2021 was $12.8 million, or 23.4% of revenue, compared to $14.8 million, or 25.0% of revenue, for the same period in fiscal 2020. Adjusted for nonrecurring expenses, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expense for the fourth quarter of fiscal 2021 was $13.6 million, or 24.8% of revenue, compared to adjusted non-GAAP SG&A expense for the fourth quarter of fiscal 2020 of $14.3 million, or 24.1% of revenue. The year over year decrease in non-GAAP SG&A expense was primarily due to decreased stock and incentive compensation expenses due to performance against current year bonus targets as well as the departure of executives during the current year period.
Operating income for the fourth quarter of fiscal 2021 was $6.6 million, or 12.0% of revenue, compared to $6.2 million, or 10.5% of revenue, for the fourth quarter of fiscal 2020. Accounting for the non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the fourth quarter of fiscal 2021 was $5.8 million, or 10.6% of revenue, compared to $6.7 million, or 11.3% of revenue, for the fourth quarter of fiscal 2020.
Net income for the fourth quarter of fiscal 2021 was $4.9 million, or $0.35 per diluted share. This compares to net income for the fourth quarter of fiscal 2020 of $3.8 million, or $0.26 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the fourth quarter of fiscal 2021 increased 4.6% to $4.3 million, or $0.31 per diluted share. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for the fourth quarter of fiscal 2020 was $4.1 million, or $0.28 per diluted share. The Company’s effective tax rate decreased to 24.3% in the fourth quarter of fiscal 2021 compared to 37.2% in the prior year period. The decrease in the tax rate in the current year period positively impacted adjusted earnings per share by approximately $0.05.
Adjusted EBITDA decreased 19.3% to $6.6 million for the fourth quarter of fiscal 2021, compared to $8.2 million for the comparable period in fiscal 2020.
Fiscal 2021 Full Year Results
For the fiscal year ended June 30, 2021, the Company reported net revenue of $220.2 million, a decrease of 5.5% compared to $232.9 million for fiscal 2020. In fiscal 2021, revenue in the Americas decreased 7.0% and revenue in Asia/Pacific & Europe decreased 1.6%. Revenue for fiscal 2020 was positively impacted $2.6 million, or 1.1%, by foreign currency fluctuations associated with revenue generated in international markets when compared to fiscal year 2020.
Gross profit during fiscal 2021 was $182.0 million, or 82.7% of revenue, compared to $195.0 million, or 83.7% of revenue, for fiscal 2020. The decrease in gross margin as a percentage of revenue is primarily due to increased shipping expenses as global demand for shipping increased significantly due to the COVID-19 pandemic.


logoa23a.jpg

Commissions and incentives expense for fiscal 2021 was $103.5 million, or 47.0% of revenue, compared to $111.6 million, or 47.9% of revenue, for fiscal 2020. Commissions and incentives expense as a percentage of revenue decreased as a result of the cancellation of incentive events during the year due to the COVID 19 pandemic and associated travel and meeting restrictions as well as the continued refinement and the timing and magnitude of our various promotional and incentive programs during the year.
SG&A expense for fiscal 2021 was $60.8 million, or 27.6% of revenue, compared to $67.9 million, or 29.2% of revenue, for fiscal 2020. Adjusted for nonrecurring expenses and recoveries, which are detailed in the GAAP to non-GAAP reconciliation tables included at the end of this press release, adjusted non-GAAP SG&A expense for fiscal 2021 was $59.2 million, or 26.9% of revenue, compared to adjusted non-GAAP SG&A expense for fiscal 2020 of $66.7 million, or 28.6% of revenue. The year over year decrease in non-GAAP SG&A expense was primarily due to the cancellation of in-person events and decreased travel expenses related to the restrictions associated with the COVID-19 pandemic, as well as lower stock and incentive compensation expense due to performance against current year bonus targets as well as the departure of executives during the current year.
Operating income for fiscal 2021 was $17.6 million, or 8.0% of revenue, compared to $15.5 million, or 6.6% of revenue, for fiscal 2020. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for fiscal 2021 was $19.2 million, or 8.7% of revenue, compared to $16.7 million, or 7.2% of revenue, for fiscal 2020.
Net income for fiscal 2021 was $12.9 million, or $0.90 per diluted share, compared to $11.5 million, or $0.79 per diluted share for fiscal 2020. Accounting for the non-GAAP adjustments noted previously, net of tax, adjusted non-GAAP net income for fiscal 2021 increased 14.4% to $14.3 million, or $1.00 per diluted share. This compares to adjusted non-GAAP net income for fiscal 2020 of $12.5 million, or $0.86 per diluted share. On a non-GAAP basis, the Company’s effective tax rate increased to 24.1% in fiscal 2021 compared to an effective tax rate of 21.6% in the prior year. The increase in the current year tax rate negatively impacted adjusted earnings per share by approximately $0.03.
Adjusted EBITDA increased 3.7% to $24.8 million for fiscal 2021, compared to $24.0 million for fiscal 2020.
Balance Sheet & Liquidity
The Company generated $16.3 million of cash from operations during fiscal 2021 compared to $18.3 million during fiscal 2020. The Company's cash and cash equivalents at June 30, 2021 were $23.2 million, compared to $22.1 million at June 30, 2020. The Company had no debt outstanding at June 30, 2021 and 2020, respectively. During the fourth quarter of fiscal 2021, the Company repurchased approximately 0.5 million common shares for $3.9 million under its share repurchase program.
Fiscal Year 2022 Guidance
The Company expects to generate revenue in the range of $225 million to $235 million in fiscal year 2022 and adjusted EBITDA of $22 million to $24 million, with adjusted earnings per share in the range of $0.83 to $0.87, which assumes a full year tax rate of approximately 26%. This guidance reflects the current trends in the business and the Company’s current view as to the impact of the COVID-19 pandemic on its business. The Company's guidance for adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share excludes any non-operating or non-recurring expenses that may materialize during fiscal 2022. The Company is not providing guidance for GAAP earnings per diluted share for fiscal 2022 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.


logoa23a.jpg
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 705-6003 from the U.S. International callers can dial (201) 493-6725. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, August 26, 2021, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13721246, or (412) 317-6671 from international locations, and entering confirmation code 13721246.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at http://investor.lifevantage.com/events-and-presentations or directly at http://public.viavid.com/index.php?id=145578.The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company’s line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, and Daily Wellness dietary supplements, TrueScience® is the Company's line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio® its nootropic energy drink mixes, and PhysIQ™, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected financial performance. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-


logoa23a.jpg
time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.

Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com


logoa23a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
As of
(In thousands, except per share data)June 30, 2021June 30, 2020
ASSETS
Current assets
Cash and cash equivalents$23,174 $22,138 
Accounts receivable2,925 2,610 
Income tax receivable1,038 — 
Inventory, net16,145 13,888 
Prepaid expenses and other4,772 5,232 
     Total current assets48,054 43,868 
Property and equipment, net11,123 7,170 
Right-of-use assets13,700 956 
Intangible assets, net719 851 
Deferred income tax asset1,208 2,164 
Equity securities2,205 2,205 
Other long-term assets1,723 1,663 
TOTAL ASSETS$78,732 $58,877 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable$6,744 $3,521 
Commissions payable8,138 9,219 
Income tax payable830 784 
Lease liabilities2,151 1,184 
Other accrued expenses7,336 10,311 
Current portion of long-term debt, net— — 
Total current liabilities25,199 25,019 
Long-term lease liabilities16,032 — 
Other long-term liabilities694 604 
     Total liabilities41,925 25,623 
Commitments and contingencies
Stockholders' equity
Preferred stock — par value $0.0001 per share, 5,000 shares authorized, no shares issued or outstanding
— — 
Common stock — par value $0.0001 per share, 40,000 shares authorized and 13,609 and 14,113 issued and outstanding as of June 30, 2021 and 2020, respectively
Additional paid-in capital129,048 126,416 
Accumulated deficit(92,346)(93,307)
Accumulated other comprehensive income104 144 
     Total stockholders’ equity 36,807 33,254 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$78,732 $58,877 


logoa23a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
For the Three Months Ended June 30,
(unaudited)
Fiscal Year Ended June 30,
(In thousands, except per share data)2021202020212020
Revenue, net$54,777 $59,368 $220,181 $232,915 
Cost of sales9,782 9,449 38,187 37,964 
Gross profit44,995 49,919 181,994 194,951 
Operating expenses:
Commissions and incentives25,603 28,894 103,541 111,571 
Selling, general and administrative12,811 14,816 60,838 67,914 
Total operating expenses38,414 43,710 164,379 179,485 
Operating income6,581 6,209 17,615 15,466 
Other expense:
Interest expense— (1)(17)(120)
Other expense, net(103)(120)(366)(685)
Total other expense(103)(121)(383)(805)
Income before income taxes6,478 6,088 17,232 14,661 
Income tax expense(1,571)(2,264)(4,338)(3,112)
Net income$4,907 $3,824 $12,894 $11,549 
Net income per share:
Basic$0.36 $0.27 $0.92 $0.82 
Diluted$0.35 $0.26 $0.90 $0.79 
Weighted-average shares outstanding:
Basic13,754 14,258 14,070 14,105 
Diluted13,879 14,703 14,268 14,599 



logoa23a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Revenue by Region
Three Months Ended June 30,
(unaudited)
Fiscal Year Ended June 30,
(In thousands)2021202020212020
Americas$37,677 69 %$41,690 70 %$154,655 70 %$166,336 71 %
Asia/Pacific & Europe17,100 31 %17,678 30 %65,526 30 %66,579 29 %
Total$54,777 100 %$59,368 100 %$220,181 100 %$232,915 100 %
Active Accounts
(unaudited)
As of June 30,
20212020Change from Prior YearPercent Change
Active Independent Distributors(1)
    Americas41,000 65 %49,000 67 %(8,000)(16.3)%
    Asia/Pacific & Europe22,000 35 %24,000 33 %(2,000)(8.3)%
        Total Active Independent Distributors63,000 100 %73,000 100 %(10,000)(13.7)%
Active Customers(2)
    Americas78,000 73 %83,000 78 %(5,000)(6.0)%
    Asia/Pacific & Europe29,000 27 %23,000 22 %6,000 26.1 %
        Total Active Customers107,000 100 %106,000 100 %1,000 0.9 %
Active Accounts(3)
    Americas119,000 70 %132,000 74 %(13,000)(9.8)%
    Asia/Pacific & Europe51,000 30 %47,000 26 %4,000 8.5 %
        Total Active Accounts170,000 100 %179,000 100 %(9,000)(5.0)%
(1) Active Independent Distributors have purchased product in the prior three months for retail or personal consumption.
(2) Active Customers have purchased product in the prior three months for personal consumption only.
(3) Total Active Accounts is the sum of Active Independent Distributors and Active Customers.


logoa23a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA:
(Unaudited)
Three Months Ended June 30,Fiscal Year Ended June 30,
(In thousands)2021202020212020
GAAP Net income$4,907 $3,824 $12,894 $11,549 
Interest expense— 17 120 
Provision for income taxes1,571 2,264 4,338 3,112 
Depreciation and amortization(1)
817 824 3,460 2,777 
Non-GAAP EBITDA:7,295 6,913 20,709 17,558 
Adjustments:
Stock compensation expense(79)838 2,036 4,919 
Other expense, net103 120 366 685 
Other adjustments(2)
(700)334 1,736 806 
Total adjustments(676)1,292 4,138 6,410 
Non-GAAP Adjusted EBITDA$6,619 $8,205 $24,847 $23,968 
(1) Includes $101,000 of accelerated depreciation related to a change in lease term and $335,000 leasehold depreciation for the fiscal year ended June 30, 2021. Includes $152,000 and $456,000 of accelerated depreciation related to a change in lease term for the three months and fiscal year ended June 30, 2020.
(2) Other adjustments breakout:
Lease abandonment$— $— $495 $— 
Class-action lawsuit expenses, net of recoveries$(1,002)$334 $(144)$703 
Executive team severance expenses, net160 — 851 — 
Executive team recruiting and transition expenses142 — 534 — 
Other nonrecurring legal and accounting expenses— — — 103 
Insurance reimbursement— — — — 
Change in estimate of accrued import liabilities— — — — 
Total adjustments$(700)$334 $1,736 $806 



logoa23a.jpg
LIFEVANTAGE CORPORATION AND SUBSIDIARIES
Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS:
(Unaudited)
Three Months Ended June 30,Fiscal Year Ended June 30,
(In thousands)2021202020212020
GAAP Net income$4,907 $3,824 $12,894 $11,549 
Adjustments:
Executive team severance expenses, net(1)
83 — 269 — 
Executive team recruiting and transition expenses142 — 534 — 
Lease abandonment(2)
— — 830 — 
Class-action lawsuit expenses, net of recoveries(1,002)334 (144)703 
Other nonrecurring legal and accounting expenses— — — 103 
Accelerated depreciation related to change in lease term— 152 101 456 
Tax impact of adjustments188 (181)(192)(323)
Total adjustments, net of tax(589)305 1,398 939 
Non-GAAP Net Income$4,318 $4,129 $14,292 $12,488 
Three Months Ended June 30,Fiscal Year Ended June 30,
2021202020212020
Diluted earnings per share, as reported$0.35 $0.26 $0.90 $0.79 
Total adjustments, net of tax(0.04)0.02 0.10 0.06 
Diluted earnings per share, as adjusted(3)
$0.31 $0.28 $1.00 $0.86 
(1) Net of $77,000 and $582,000 of compensation expense benefit related to unvested stock award reversals for the three months and fiscal year ended June 30, 2021
(2) Includes remaining lease rent expense of $495,000 and leasehold depreciation of $335,000 for the fiscal year ended June 30, 2021.
(3) May not add due to rounding.


EX-101.SCH 3 lfvn-20210819.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lfvn-20210819_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Type Document Type Entity Address, Postal Zip Code Entity Address, Postal Zip Code Local Phone Number Local Phone Number Written Communications Written Communications City Area Code City Area Code Amendment Flag Amendment Flag Title of 12(b) Security Title of 12(b) Security Entity Address, State or Province Entity Address, State or Province Security Exchange Name Security Exchange Name Soliciting Material Soliciting Material Document Period End Date Document Period End Date Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Cover [Abstract] Cover [Abstract] Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Address, Address Line One Entity Address, Address Line One Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line Two Entity Address, Address Line Two Entity Emerging Growth Company Entity Emerging Growth Company Entity Registrant Name Entity Registrant Name Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Trading Symbol Trading Symbol EX-101.PRE 5 lfvn-20210819_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 logoa23a.jpg begin 644 logoa23a.jpg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lfvn-20210819_htm.xml IDEA: XBRL DOCUMENT 0000849146 2020-08-18 2020-08-18 0000849146 false 8-K 2021-08-19 LIFEVANTAGE CORP DE 001-35647 90-0224471 3300 Triumph Blvd Suite 700 Lehi UT 84043 801 432-9000 false false false false Common Stock, par value $0.0001 LFVN NASDAQ false 2021-08-19 2021-08-19 XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page
Aug. 18, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Aug. 19, 2021
Entity Registrant Name LIFEVANTAGE CORP
Entity Central Index Key 0000849146
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-35647
Entity Tax Identification Number 90-0224471
Entity Address, Address Line One 3300 Triumph Blvd
Entity Address, Address Line Two Suite 700
Entity Address, City or Town Lehi
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84043
City Area Code 801
Local Phone Number 432-9000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol LFVN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.lifevantage.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports lfvn-20210819.htm lfvn-20210819.xsd lfvn-20210819_lab.xml lfvn-20210819_pre.xml lfvnq42021earningsrelease.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "lfvn-20210819.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "lfvn-20210819.htm" ] }, "labelLink": { "local": [ "lfvn-20210819_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "lfvn-20210819_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "lfvn-20210819.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "lfvn", "nsuri": "http://www.lifevantage.com/20210819", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20210819.htm", "contextRef": "ia4d5220ad5c942278a5b9bf93e4015a4_D20200818-20200818", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.lifevantage.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "lfvn-20210819.htm", "contextRef": "ia4d5220ad5c942278a5b9bf93e4015a4_D20200818-20200818", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.lifevantage.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000849146-21-000079-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000849146-21-000079-xbrl.zip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